We aim to develop enhanced T cell therapies to treat solid tumours. To do this, we study the dynamic nature of T-cell therapies, recognizing something many have overlooked: T cells are living, adaptable cells. By studying their behaviour, we identified targets to select the most potent T cells, those with the strongest solid tumour-targeting. This approach means that we can ensure the most effective cells are administered to patients, improving treatment outcomes. We have already demonstrated the potential of this approach, showing that by enriching T cells for our specific targets we can increase their ability to kill solid tumours.